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Abstract
This study investigated the use of Bayesian Networks (BNs) for left ventricular assist device (LVAD) therapy; a treatment for
end-stage heart failure that has been steadily growing in popularity over the past decade. Despite this growth, the number
of LVAD implants performed annually remains a small fraction of the estimated population of patients who might benefit
from this treatment. We believe that this demonstrates a need for an accurate stratification tool that can help identify LVAD
candidates at the most appropriate point in the course of their disease. We derived BNs to predict mortality at five
endpoints utilizing the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database:
containing over 12,000 total enrolled patients from 153 hospital sites, collected since 2006 to the present day, and
consisting of approximately 230 pre-implant clinical variables. Synthetic minority oversampling technique (SMOTE) was
employed to address the uneven proportion of patients with negative outcomes and to improve the performance of the
models. The resulting accuracy and area under the ROC curve (%) for predicted mortality were 30 day: 94.9 and 92.5; 90 day:
84.2 and 73.9; 6 month: 78.2 and 70.6; 1 year: 73.1 and 70.6; and 2 years: 71.4 and 70.8. To foster the translation of these
models to clinical practice, they have been incorporated into a web-based application, the Cardiac Health Risk Stratification
System (CHRiSS). As clinical experience with LVAD therapy continues to grow, and additional data is collected, we aim to
continually update these BN models to improve their accuracy and maintain their relevance. Ongoing work also aims to
extend the BN models to predict the risk of adverse events post-LVAD implant as additional factors for consideration in
decision making.
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Introduction
Cardiac transplantation currently represents the most definitive
treatment for end-stage heart failure (ESHF) with 90% 1-year
survival and a 70% 5-year survival. However, there is a need for
alternate therapies due to the limited supply of donor organs. For
those ineligible for a heart transplant, or unable to wait, an
alternative life-sparing therapy is to implant a left ventricular assist
devices (LVAD). These devices have been used for nearly 25 years
to support ESHF patients while awaiting transplant and have been
consistently shown to improve mortality. The technology has now
progressed to the point where they are offered as permanent or so-
called Destination Therapy (DT). According to current estimates,
the number of ESHF patients who may benefit from LVAD
therapy is between 80,000 and 200,000 annually. [1]
LVAD Risk Scores
Optimal and responsible use of LVAD therapy requires a
procedure for selecting patients who are most likely to benefit, and
less likely to suffer adverse complications. In general, as a patient’s
disease progresses, the probability of poor outcomes increases. It is
therefore important to identify candidates early in the progression
of their disease so as not to miss the optimal window of
opportunity [2,3]. The window is considered between INTER-
MACS level 7 and 3, where 7 is clinically stable but history of
previous decompensation and 3 is stable but Inotrope dependent
[4]. This has motivated the development of risk scores to stratify
patients based on the factors that have historically been associated
with outcomes, such as patient characteristics, advances in
mechanical circulatory support technology and surgical experi-
ence.
The most commonly cited score is the Lietz-Miller Destination
Therapy Risk Score (DTRS), which was derived from a patient
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cohort with first generation pumps [5]. The first generation
LVADs were pulsatile flow pumps, which attempted to mimic the
physiological conditions. One-year survival in subjects undergoing
the first generation pulsatile flow HeartMate XVE implantation
for DT in the Randomized Evaluation of Mechanical Assistance
for the Treatment of Congestive Heart failure (REMATCH) trial
was 52% [6]. Enrollment criteria of initial studies emphasized
hemodynamic variables. The DTRS analyzed 45 baseline
parameters and outcomes in 280 DT patients in the post-
REMATCH era. The most important determinants of in-hospital
mortality were poor nutrition, hematological abnormalities,
markers of end-organ and RV dysfunction and lack of inotropic
support. Patients were stratified into low, medium, high and very
high risk based on a score calculated from these predictors to
correspond with 1-year survival [5]. The DTRS, however, has
many limitations. The majority of patients in the derivation cohort
were ambulatory, older men with large body surface area. Co-
morbidities such as diabetes, cardiac cachexia or obesity were
under-represented, while psychosocial factors or echocardiograph-
ic parameters were not considered.
Since the DTRS was derived, there has been major advances in
the technology. In particular, second generation (continuous flow)
pumps have become available that are smaller in size, have simpler
technique for implantation, longer durability and present reduced
risk of thromboembolism, infection and malfunction. Consequent-
ly, the frequency of adverse events has diminished, which has
further expanded the candidacy pool for LVAD therapy. This has
rendered the DTRS less accurate [7]. Other risk scores have been
introduced, but are limited for a variety of reasons, such as limited
independent variables or limited training data (e.g. from a single
center.) For example, a recently introduced HeartMate II Risk
Score (HMRS) relies on only five preoperative variables for
predicting 90 day survival; the long-term (1 year) model only
contained two: age and implant center experience [8].
Clinical Decision Support Systems
The transition from paper to electronic medical records
provides both a challenge and great opportunity for clinical
decision making. On the one hand, the ever increasing quantity of
information collected on a typical LVAD patient can overwhelm a
clinical team, and arguably may introduce more uncertainty due
to data incompleteness and noisiness. On the other hand, the
wealth of information embedded in these data are ideal for
computer-based Clinical Decision Support Systems (CDSS) [9,10].
This is the motivation for developing the Cardiac Health Risk
Stratification System (CHRiSS). CHRiSS is a web-enabled
decision support tool that provides patient-specific predictions of
mortality at 5 endpoints post-implant: 30 day, 90 day, 6 month, 1
year and 2 year. It offers several advantages over traditional
LVAD risk scores. Since it is based on a Bayesian machine
learning algorithm, it can better represent the influence of large
sets of interrelated variables as compared to traditional Cox model
multivariate predictors [11,12]. Unlike most risk scores which
compute survival at one time point, CHRiSS provides predictions
of both short-term and long-term mortality. Since CHRiSS is
implemented as an interactive software application, it also permits
the user to explore various ‘‘what if’’ scenarios.
The purpose of this study is to evaluate the accuracy and
sensitivity of the Bayesian Networks (BNs) in the CHRiSS tool.
Accuracy is evaluated both in terms of True Negative (ability to
predict survival) and True Positive (ability to predict mortality),
which is also depicted by the receiver operating characteristics
(ROC) curve. Sensitivity analysis was performed to identify the
strongest predictive variables that are associated with either
increased or decreased chance of survival post-LVAD.
Methods
This study was conducted with a comprehensive dataset, known
as the Interagency Registry for Mechanically Assisted Circulatory
Support (INTERMACS). This is the largest national registry for
U.S. Food and Drug Administration (FDA) approved mechanical
circulatory support devices that is jointly sponsored by the
National Heart, Lung, and Blood Institute (NHLBI), Centers for
Medicare and Medicaid Services (CMS), FDA and industry. The
registry has over 12,000 total enrolled patients (over 8,000
continuous flow LVADs) from 153 hospital sitesand has been
collecting data since 2006 to the present day. The dataset consists
of over 300 pre-implant clinical variables, subdivided into six main
categories: demographics, co-morbidities and limitations from
transplant listing, laboratory values, hemodynamics, medications
and quality of life questionnaires and surveys. A co-morbidity in
this context is defined as a medical condition or disease that exists
simultaneously with another condition or disease. They can either
be independent or related conditions or diseases.
Patient Cohort
Institutional Review Board approval was obtained through
hospitals participating within INTERMACS. The study described
in this submission was approved by the INTERMACS Data,
Access, Analysis, and Publication Committee (DAAP). Written
informed consent was acquired from participants before being
enrolled in INTERMACS. The Data Coordinating Center at
University of Alabama at Birmingham provided us the data once it
was de-identified. The data used in the present study was
anonymized and de-identified prior to analysis. Inclusion criteria
for this study was: use of a continuous flow LVAD as the primary
implant and age.19, thus excluding pediatric patients. Patients
who ultimately received an Right Ventricular Assist Device
(RVAD) were included as long as the initial implant was an
LVAD and an RVAD was placed thereafter. The specific type of
RVAD was not considered. Total Artificial Heart recipients were
excluded from this study. This translated to 8,050 patients from
year 2006 to 2013 in the initial dataset. Data from patients whose
LVAD was electively removed (e.g., due to transplantation or
recovery) were censored at the time of event (See Table 1).
Pre-processing
The raw data from the registry was pre-processed to transform
continuous data into discrete bins (required by the Bayesian
algorithm) and to fill in missing data, described below.
Discretization. Discretization was done based on a balance
of equal frequency binning and published upper and lower limits
of clinically normal values [13,14]. Table S1 provides the list of
variables with their respective formats and input values. Clinical
scenarios and outcomes, such as events during hospitalization,
adverse events prior to implant and interventions within 48 hours
of implant, were defined using the INTERMACS definitions.
Missing data. The patient records provided by the INTER-
MACS data set were found to be routinely incomplete (see Table
S1 for percentages missing). Missing data was separated into two
categories: missing at random (MAR), and missing not at random
(MNAR) [15]. Missing demographics and lab values, for example,
were considered to be either MAR, in which case we assumed the
most probable values (i.e. BMI between 24–27 since it is
considered normal). The method of using normal values has been
cited in previous studies to produce superior results compared to
Bayesian Clinical Decision Support System for LVAD Therapy
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listwise deletion and other methods [16]. Missing co-morbidities,
on the other hand were considered MNAR, in which case we
assumed that it was not a concern for that patient. This is standard
procedure for handling MNAR data in medical datasets. For
example, if a patient has no record of a chest x-ray then the doctor
probably did not feel the need to order one. In these cases, it is
common to assume a ‘‘normal’’ value, which in the case of the x-
ray would be not ordered as opposed to unknown, or simply
missing. Additional data in the MAR category were missing
laboratory and hemodynamic values were designated as not
ordered. Missing medication data was considered MNAR, in
which we assumed that no such medication was prescribed.
Finally, missing quality of life metrics were considered MNAR,
and designated as unknown. This was justified based on voluntary
and sporadic participation in the two quality of life surveys, the
EuroQoL [17] (offered since the beginning of the registry)and the
Kansas City Cardiomyopathy Questionnaire (KCCQ) [18]
implemented after 2012.
Synthetic Minority Oversampling Technique (SMOTE)
A common challenge in data mining that inhibits the predictive
ability of the model, is an uneven distribution of the outcome
(survival post-LVAD). In medicine, there is often a larger portion
of the cohort that are free of death or adverse event as compared
to the number of events. The 30-day mortality rate in
INTERMACS is 4.8%, compared to a 95.2% survival rate. With
such a discrepancy, the model will always predict the majority
class (survival) if uncertain how to classify a new patient. This will
pose a setback clinically, as it is most important to identify the
high-risk patients (early mortality).
One of the most frequently cited methods for addressing this
bias is SMOTE [19], which is used when the minority class is
increased by creating synthetic examples rather than by over-
sampling with replacement. The minority class (mortality) is over-
sampled by taking each minority class sample and introducing
synthetic examples along the line segments joining any or all of the
k minority class nearest neighbors. For this study we increased the
minority class by 100%, which would essentially double the
mortality number at each endpoint, while the survival number
remained unchanged. The 100% was identified by incrementally
increasing the percentage from 0% to 100% and identifying the
best performing percentage. We set the cut off at 100% to ensure
there would be at least an even number of actual and synthetic
cases, as opposed to more synthetic compared to actual cases.
Synthetic samples are generated by taking the difference between
the instance (or patient) under consideration and its nearest
neighbor. This difference was multiplied by a random number
between 0 and 1, and added to the feature vector under
consideration. (This causes the selection of a random point along
the line segment between two specific features.) SMOTE
effectively forces the decision region of the minority class to
become more general. Table 1 juxtaposes the dataset before and
after application of SMOTE.
Bayesian Networks
The machine learning methods used for the present study were
built upon Bayesian techniques used previously by our group for
multiple decision support studies, including: optimal VAD
weaning [20], the need for right ventricular support due to right
ventricular failure [21–23] and a two-center study to predict 90-
day survival for continuous flow LVADs [24,25]. Bayesian
networks (BNs) [26] are acyclic directed graphs in which nodes
represent random variables and directed arcs (represented as
arrows) between pairs of variables represent influences between
them. In addition to the graph structure, a BN is equipped with
conditional probability tables (CPT), associated with each node,
and describes the probability distribution over the variable’s values
conditional on all combinations of values of its immediate
predecessors (parents) in the graph. A BN is a representation of
a factorization of the joint probability distribution over its
variables. Independence between a pair of variables is represented
by absence of a directed arrow between these variables. Explicit
representation of independences results in significant savings in the
number of parameters necessary to represent the complete joint
probability distribution, making BNs highly practical even in very
complex domains.
The joint probability distribution represented by a BN can be
updated in the light of new evidence by means of Bayes theorem.
Efficient algorithms exist that given observed values of some of the
variables, produce the new joint (conditional) probability distri-
bution over the remaining variables. While the quality of the
results rests on the quality of the underlying representation of the
joint probability distribution, BNs have been shown to be very
robust to precision of their parameters [27] and there are
indications that possible errors in structure (i.e., incorrect
independences) have also limited influence on the quality of the
results [28].
To illustrate, one may consider a simple BN model in Figure S1,
modeling risk factors related to LVAD survival. The network
models the joint probability distribution over the four factors and
the survival variable. Not all variables need to be known. For
example, we could derive from the network the average survival
probability for a center with limited LVAD experience.
For this study, we evaluated four BNs: Na¨ıve Bayes, Tree-
Augmented Na¨ıve Bayes, Bayesian Search and the Greedy Thick
Thinning Algorithm [29]. We ultimately chose the Greedy Thick
Thinning Algorithm as the final model based on a tradeoff
between complexity and accuracy. The model starts with an
empty graph and iteratively adds and removes arcs as it builds the
Table 1. Mortality statistics, censored for explant and transplant.
Endpoint Survival No. (%) Death No. (%) Total Survival SMOTE No. (%) Death SMOTE No. (%) Total SMOTE No. (%)
30 Day 7620 (95.2) 387 (4.8) 8007 7620 (90.8) 774 (9.2) 8394
90 Day 7024 (90.5) 737 (9.5) 7761 7024 (82.6) 1474 (17.3) 8498
6 Month 6245 (86.1) 1007 (13.9) 7252 6245 (75.6) 2014 (24.4) 8259
1 Year 5241 (79.7) 1334 (20.3) 6575 5241 (66.2) 2668 (33.7) 7909
2 Year 4432 (72.7) 1667 (27.3) 6099 4432 (57.1) 3334 (42.9) 7766
SMOTE: synthetic minority oversampling technique.
doi:10.1371/journal.pone.0111264.t001
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network, incrementally increasing the Bayesian scoring metric: in
this case, the K2 prior distribution over the parameters [30].
Markov Blanket
We applied the Markov Blanket to simplify the network and
reduce the likelihood of over-fitting the model to the dataset (i.e.
performs well only on the training data, but unable to generalize to
other datasets). It has been shown in previous studies that using the
Markov Blanket is one of the most effective and efficient methods
of feature selection [31]. The Markov Blanket for each of the BN
models was comprised of the class node and the family of nodes
that make it conditionally independent of all other nodes in the
network. This includes the parents, the children and the parents of
the children, or spouses [26].
Evaluation
Ten-fold cross validation was the vehicle for model derivation
and optimization. The BN classifiers were evaluated on an
independent testing/holdout dataset comprised of a training set of
approximately 90% of the data records and a testing set from the
remaining approximate 10%. The models were derived, built and
implemented using two open-source machine learning software
libraries: The GeNIe modeling environment developed by the
Decision Systems Laboratory of the University of Pittsburgh [32]
and the machine learning library WEKA (Waikato Environment
for Knowledge Analysis) [33]. Performance metrics included:
Accuracy, True Positive, True Negative and area under the ROC
curve (AUC). A sensitivity analysis was also performed, where all
variables are kept constant and a single parameter is changed to
observe the direct affects. This is then expanded to change
additional parameters to visualize their additive affects.
Results
The optimized BNs can be seen in Figures 1–5, and a summary
of their performance can be found in Table 2. Accuracy was
greatest for the 30 day model with 95% and lowest for the 2 year
model with 71%. The True Positive (proportion of patients who
were correctly predicted to not survive) was greatest for the 2 year
at 65% and lowest for the 90 day model at 23%. The True
Negative (proportion of patients who were correctly predicted to
survive past the endpoint) was greatest for the 30 day model at
nearly 100% and lowest for the 2 year model at 76%. The ROC
% was greatest for the 30 day model at 93% and lowest for the 6
month, 1 year and 2 year models (all 71%).
30 Day Model
The 30-day mortality model consisted of 44 nodes and 93 arcs.
There are four parent nodes for 30 day mortality: whether or not a
patient completed the EuroQoL survey, a history of HIV, implant
year, and left ventricular end diastolic dimension (LVEDD), an
indicator of dilated cardiomyopathy. Positive HIV was the
strongest predictive node, followed by the implant year. When a
Figure 1. 30 Day Bayesian Model. Node colors: red = class, blue = parent, purple = child. Question marks identify nodes that do not have specific
evidence set and use the population distribution as the prior distribution. LVEDD= left ventricle end diastolic diameter, ALT = alanine transaminase,
BP = blood pressure, mRAP= mean right atrial pressure, PCWP= pulmonary capillary wedge pressure, VAS= visual analog scale, BNP= B-type
natriuretic peptide, WBC= white blood cell, NYHA= New York Heart Association functional class, RVEF = right ventricle ejection fraction, INR=
international normalized ratio, BMI = body mass index, ECG= Electrocardiography, QOL = quality of life, hx HIV = history of human
immunodeficiency virus.
doi:10.1371/journal.pone.0111264.g001
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patient is indicated to have a history of HIV, then the baseline
likelihood of survival drops from 95% (when no patient-specific
evidence is specified) to 53% and drops further to 43% chance of
survival when the LVEDD is above 75 mm. The children nodes
includes a combination of laboratory values (sodium, BNP and
platelets), hemodynamics (mean right arterial pressure, diastolic
blood pressure and ECG rhythm), demographics (age and gender)
and pre-implant medication (beta blockers, aldosterone and
amiodarone). This model was the one exception to using the
Markov Blanket, as it would approach nearly 150 nodes with the
inclusion of the spousal nodes and would be more prone to over-
fitting the dataset. For the model, we simply used the parents and
children nodes, which put it at a comparable size as the other
endpoint Bayesian models.
90 Day Model
The 90-day model consisted of 30 nodes and 56 arcs. There are
four parent nodes: gender, co-morbidity of HIV, cholesterol and
pulmonary capillary wedge pressure. History of HIV decreased
90-day chance of survival from 87% to 52% and, when combined
with elevated cholesterol (above 150 mg/dL), further decreases to
47%. The chance of survival increases (as compared to the
baseline) to 91% if a patient’s cholesterol is below 110 mg/dL and
they do not have HIV. The children nodes include variables such
as mitral regurgitation, right ventricular ejection fraction and work
income. Spouse nodes include tricuspid and aortic regurgitation,
pre-implant beta blockers, pre-implant ace inhibitors, and left
ventricular ejection fraction.
6 Month Model
The 6-month model consisted of 34 nodes and 70 arcs. There
are five parent nodes: limitation for transplant due to thoracic
aortic disease, creatinine, number of cardiac hospitalizations
within the 12 months prior to LVAD implant, cholesterol and
HIV. Compared to the baseline chance of survival at 6 months of
76%, the limitation for transplant reduces to 48%, and when
combined with creatinine levels below 1.1 mg/dL further reduces
to 37%. The children nodes include variables such as BMI, work
income and angiotensin. Spouse nodes include presence of an
implantable cardioverter defibrillator (ICD), admission reason
before implant, history of gastrointestinal bleeding, limitation for
transplant listing due to advanced age, and the INTERMACS
profile (from level 1 critical cardiogenic shock to level 7 resting
heart failure symptoms but stable).
1 Year Model
The 1-year model consisted of 39 nodes and 76 arcs. There are
six parent nodes: co-morbidity of HIV, limitation for transplant
Figure 2. 90 Day Bayesian Model. Node colors: red = class, blue = parent, purple = child, yellow= spouse. Question marks identify nodes that do
not have specific evidence set and use the population distribution as the prior distribution. LVEDD= left ventricle end diastolic diameter, PCWP=
pulmonary capillary wedge pressure, RVEF= right ventricle ejection fraction, LVEF = left ventricle ejection fraction, hx HIV = history of human
immunodeficiency virus, ICD= implantable cardioverter defibrillator, Lim tx = limitation for transplant listing, GI = gastrointestinal, IV = intravenous.
doi:10.1371/journal.pone.0111264.g002
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listing due to thoracic aortic disease, gender, implant year,
limitation for transplant listing due to pulmonary hypertension
and cholesterol. The baseline chance of survival at 1 year post-
implant is 75%, and more recent implants (2013) have higher
chances of survival (86%) compared to implants done between
2008–2010 (64–66%). Although this is likely due to shorter follow
up times for the more recent implants, it may also reflect advances
in implant techniques and changes in the patient post-VAD
management. Similar to the other models, both a history of HIV
and thoracic aortic disease have major impacts on the chance of 1
year survival. The children nodes include age, right ventricular
ejection fraction, BMI, ace inhibitors and diastolic blood pressure.
Spouse nodes include admission reason, systolic blood pressure,
the INTERMACS profile, temporary mechanical circulatory
device, current ICD and co-morbidity due to cachexia (malnutri-
tion).
2 Year Model
The model for 2-year mortality consisted of 45 nodes and 78
arcs. There are eight parent nodes: pro-BNP, BNP, co-morbidity
of solid organ cancer, implant year, gender, limitation for
transplant listing due to limited social support, patient refusal for
transplant listing, and limitation for transplant listing due to large
BMI. The baseline 2-year chance of survival is 69%, which
increases by 5% if the patient’s BNP levels are below 540 pg/dL
and increases further to 84% if the implant was done more
recently. The chance of survival falls below the baseline (to 62%) if
BNP is elevated above 1200 pg/dL, drops further to 58% if the
patient declines transplant listing and drops even further to 50% if
the patient also has limited social support. The children nodes
included age, trail making time (a neuro-psychological test of
visual attention and task switching), co-morbidity due to a history
of illicit drug use and blood type. Spousal nodes included
limitation for transplant listing due to peripheral vascular disease,
the INTERMACS profile, being a so-called frequent flyer (patients
who are repeatedly in and out of the hospital emergency room),
the IV inotrope therapy agent and age.
HMRS
The HMRS was derived and validated for 90-day and 1-year
mortality and identifies patients as either low risk (4–8%
mortality), medium risk (11–16% mortality) or high risk (25–
29% mortality). When applied to the INTERMACS database,
93.1% of patients were predicted as low risk with a 9% morality
rate, 4.4% were predicted as medium risk with a 16% mortality
rate, and 2.3% were predicted as high risk with a 14.6% mortality
rate. The ROC for the 90-day HMRS score was 60.3% compared
to 73.9% for the 90-day CHRiSS model and the 1-year HMRS
score 57.4% compred to 70.9% for the 1-year CHRiSS model.
Discussion
The decision to refer a patient for LVAD therapy entails
processing numerous, dynamically evolving and inter-related
Figure 3. 6 Month Bayesian Model. Node colors: red = class, blue = parent, purple = child, yellow= spouse. Question marks identify nodes that
do not have specific evidence set and use the population distribution as the prior distribution. LVEDD= left ventricle end diastolic diameter, RVEF=
right ventricle ejection fraction, LVEF= left ventricle ejection fraction, hx HIV= history of human immunodeficiency virus, BMI = body mass index,
ICD= implantable cardioverter defibrillator, Lim tx = limitation for transplant listing, GI = gastrointestinal, IV = intravenous.
doi:10.1371/journal.pone.0111264.g003
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clinical variables, which is a complex task filled with uncertainty.
The trajectory by which a patient may be offered the option to
receive a LVAD involves multiple specialties and decision points.
The extensive volume of information and data that must be
considered (demographics, labs, history, family support, insurance,
etc.) is at odds with the rapidity with which some decisions must be
made. Deferring a decision to implant an LVAD, may allow the
severity of ESHF to progress thereby increasing the likelihood of
an adverse event. Lietz and Miller describe an ‘‘optimal window’’
for LVAD implantation, beyond which the operative risk may
deem the intervention futile. However, the key to successful and
timely implementation of LVAD therapy is the proper identifica-
tion of the patient who will benefit from this type of therapy:
before clinical instability occurs, which has a major impact on the
downstream morbidity and mortality with this intervention.
The advanced heart failure team must evaluate risk in terms of
both immediate complications as well as likelihood of repeated
readmissions due to longer-term complications. Hence there is a
need for a CDSS to aid the physicians in pre-LVAD candidate
assessment, by providing personalized risk predictions to ultimate-
ly encourage earlier intervention in the appropriate patients. We
envision two steps (with iteration) when using CHRiSS: the
clinician would first input the variables available for that patient
and calculate their initial risk and then adjust actionable variables
to perform the ‘‘what if’’ scenarios. For example, a clinician
assessing a patient who is initially malnourished (has lower levels of
albumin), could then adjust the albumin to the normal range and
see if the prognosis improves and by how much.
Such a dynamic CDSS does not exist for advanced HF patients
and the BNs offer several advantages over the traditional statistical
methods used to derive risk scores such as the HMRS or DTRS.
Current risk scores are limited by their: (1) simplistic four to nine
variable summed scoring system; (2) inability to co-evolve with the
changing HF risk factors and emerging treatment options; and (3)
requirement to know a fixed set of variables and inability to be
computed when any are missing. BNs address these limitations, as
they are able to: (1) account for hundreds of inter-related variables
in a single model; (2) dynamically update as risk factors change
and different drugs are created; and (3) compute predictions with
missing values by using the prior probabilities encoded within each
variable node. The current study demonstrated the potential for
developing advanced CDSS based on these models in the domain
of HF, as well as other medical applications.
For example, in the absence of any decision tool, expert
judgment resulted in the correct prognosis of survival at 1 year
79.7% (n= 5241 patients) of the time (true survival rate, see
Table 1). This translates to 20.3% (n= 1334 patients) frequency of
incorrect judgment of survival. (Presuming that the decision to
implant an LVAD in these patients was predicated on positive 1-
year survival prognosis.) With the added contribution of CHRiSS
in decision-making, 85.3% (see True Negative in Table 2) of these
79.7% (actual survival from Table 1) would be corroborated by
the prognostic model. Thereby denying an LVAD from 14.7% of
these patients who would have survived, had the physician
followed CHRiSS recommendation. On the other hand, the
expert incorrectly predicted survival in 20.3% (n= 1334, mortality
Figure 4. 1 Year Bayesian Model. Node colors: red = class, blue = parent, purple = child, yellow= spouse. Question marks identify nodes that do
not have specific evidence set and use the population distribution as the prior distribution. LVEDD= left ventricle end diastolic diameter, RVEF=
right ventricle ejection fraction, BMI = body mass index, lim tx PH= limitation for transplant listing due to pulmonary hypertension, IV = intravenous,
ICD= implantable cardioverter defibrillator, CV= cardiovascular, GI = gastrointestinal, BP = blood pressure, hx HIV = history of human
immunodeficiency virus, MCS= mechanical circulatory support.
doi:10.1371/journal.pone.0111264.g004
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% from Table 1). CHRiSS would have predicted almost half of
these patients, hence sparing 667 patients from a suboptimal
outcome. Although there is no way of knowing, retrospectively,
how long these LVAD patients would have survived if they did not
receive a LVAD, the additional insight provided by CHRiSS
would assist the patient and physician in weighing the risks and
benefits of the various courses of treatment. For example, these
patients may be prioritized for cardiac transplantation, thereby
making better use of limited organ supply for those who would not
otherwise survive on a LVAD (in exchange for a transplant patient
who would have done just as well on a LVAD.)
The 2-year CHRiSS model correctly identified 65% of patients
who would not survive past the endpoint, which would be very
important to know for DT patients to decide if they wish to accept
this risk considering chance of surviving (and thriving) for many
years with this end of life treatment. Following the same logic for
predicting short-term outcomes, CHRiSS would spare half of the
387 patients from undergoing a major surgery who would do very
poorly during the recovery post-implant. The 30-day model could
aid in vetting potential high risk DT and bridge to transplant
(BTT) candidates. Paradoxically, the performance of the 90-day
and 6-month models were not as good as the 30-day, 1-year, and
2-year models. This may be attributable to the heterogeneity in
causes of death, which may confound the Bayesian Network to
identify specific predictive variables.
Figure 5. 2 Year Bayesian Model. Node colors: red = class, blue = parent, purple = child, yellow= spouse. Question marks identify nodes that do
not have specific evidence set and use the population distribution as the prior distribution. LVEDD= left ventricle end diastolic diameter, BNP= B-
type natriuretic peptide, LVEF = left ventricle ejection fraction, GI = gastrointestinal, IV = intravenous, ICD= implantable cardioverter defibrillator,
PVD= peripheral vascular disease, hx HIV = history of human immunodeficiency virus, BMI = body mass index, MCS= mechanical circulatory
support, CV= cardiovascular.
doi:10.1371/journal.pone.0111264.g005
Table 2. Summary of Bayesian Model Performance.
Endpoint Accuracy (%) True Positive (Dead) (%) True Negative (Alive) (%) ROC (%)
30 Day 94.9 51.0 99.4 92.5
90 Day 84.2 22.9 97.1 73.9
6 Month 78.2 30.3 93.7 70.6
1 Year 73.1 49.1 85.3 70.6
2 Year 71.4 65.0 76.2 70.8
ROC= receiver operating characteristic curve.
doi:10.1371/journal.pone.0111264.t002
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We had also conducted a sensitivity analysis to observe the
direct effects of each variable on the outcome, as well as the
additive effects of several variables. The variables that created the
greatest effect on the outcome were presented in the results section
for each model. For the short-term outcome, positive HIV
increased likelihood of mortality by 42% at 30-days and 35% at
90-days. Each of these percentages were further increase by 5–
10% when adding an enlarged LVEDD (dilated cardiomyopathy)
or elevated cholesterol, respectively. When considering long-term
predictors (2-year model), one of the parent nodes was BNP, which
had bi-modal effects: normal levels lead to reduced chance of
mortality by 5% and elevated levels increased mortality by 7%.
The use and acceptance of Bayesian methodology are becoming
increasingly prevalent in the medical community (see, for example
[34–42]). For example, in 2010, the FDA released a guidance for
the use of Bayesian statistics in medical device clinical trials [43].
In 2013, the United Network for Organ Sharing (UNOS)
proposed the adoption of a new Bayesian methodology to better
identify those transplant programs that may be underperforming
in the area of patient and graft survival.
Although the methods described in this study are more
advanced than the current risk scores used in HF prognosis, the
results are far from perfect. There are several limitations that may
adversely affect performance, including inherent retrospective
bias, imbalance of the outcome variable, and extensive missing
data. We aim to address these limitations in our ongoing
prospective studies. It is also important to clarify that the CHRiSS
models are able to discern likelihood of mortality for patients
receiving an LVAD and does not allude to any predictions for
patients not receiving the device. We plan to perform a follow up
study that will derive BN models based on both INTERMACS
data, as well as a HF cohort for those who do not receive an
LVAD. Nevertheless, the current models are able to provide
decision support to the HF clinicians regarding potential future
LVAD recipients.
This study was the first application of the Bayesian Network
algorithm to a cohort of LVAD recipients. Although the current
models outperform the current LVAD risk scores, there is an
opportunity to improve them yet further as additional prospective
data is collected, and additional risk factors are added to the
model. Most certainly, the Bayesian models better represent the
complex inter-variable relationships between clinical variables,
better emulating human logic, which in turn makes them more
appealing to end users.
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